Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study.

Piotr EderMaria KłopockaHalina Cichoz-LachRenata Talar-WojnarowskaMaria Kopertowska-MajchrzakAgata MichalakRafał FilipKatarzyna WaszakKamila Stawczyk-EderMaria JaniakKrzysztof SkrobotAriel LiebertHubert ZatorskiAnna Solarska-PółchłopekMichał KroguleckiAnna PękałaElżbieta PoniewierkaIzabela SmołaAleksandra KaczkaKrzysztof WojciechowskiSzymon DrygałaEdyta Zagórowicz

Published in: Therapeutic advances in gastroenterology (2023)

ENCePP (EUPAS34119).

Keyphrases

ulcerative colitis
cross sectional
randomized controlled trial
type diabetes
stem cells
clinical trial
mesenchymal stem cells
skeletal muscle
bone marrow
cell therapy
study protocol
placebo controlled